Evidence map›Paper›PMID 39682190›Full record

ArticleCancers2024

Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study.

Pau Abrisqueta-Costa, José Antonio García-Marco, Antonio Gutiérrez, José Ángel Hernández-Rivas, Rafael Andreu-Lapiedra, Miguel Arguello-Tomas, Carolina Leiva-Farré, María Dolores López-Roda, Ángel Callejo-Mellén, Esther Álvarez-García and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pau Abrisqueta-CostaHaematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0001-9625-7422
José Antonio García-MarcoHaematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.ORCID 0000-0002-8993-5982
Antonio GutiérrezHaematology Department, Hospital Son Espases, IdISBa, 07120 Palma de Mallorca, Spain.ORCID 0000-0001-9062-077X
José Ángel Hernández-RivasHaematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, 28051 Madrid, Spain.ORCID 0000-0003-4550-757X
Rafael Andreu-LapiedraHaematology Department, Hospital Universitario La Fe, 46026 Valencia, Spain.
Miguel Arguello-TomasHaematology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0002-3329-4151
Carolina Leiva-FarréMedical Department, Astrazeneca Farmacéutica Spain S.A., 28050 Madrid, Spain.
María Dolores López-RodaMedical Department, Astrazeneca Farmacéutica Spain S.A., 28050 Madrid, Spain.
Ángel Callejo-MellénMedical Department, Astrazeneca Farmacéutica Spain S.A., 28050 Madrid, Spain.
Esther Álvarez-GarcíaMedical Department, Astrazeneca Farmacéutica Spain S.A., 28050 Madrid, Spain.
Javier LoscertalesHaematology Department, Hospital Universitario de la Princesa, 28004 Madrid, Spain.ORCID 0000-0003-3561-3758

Funding

AstraZeneca (Spain) NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse eventsartificial intelligencechronic lymphocytic leukaemiaelectronic health recordshealthcare resource utilizationnatural language processingreal-world evidence

Identifiers

PMID39682190
PMCPMC11639754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.